Drug Pipeline

Sinemet CR Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12

Active Studies

Recruiting

Top Sponsors

Changes, 30 Days

What Changed in the Last 30 Days

Detected	Trial	Change
2026-05-29	NCT04469959 Dopaminergic Dysfunction in Late-Life Depression	Trial completed
2026-05-29	NCT04469959 Dopaminergic Dysfunction in Late-Life Depression	Enrollment reduced: 100 -> 79 participants
2026-05-29	NCT04469959 Dopaminergic Dysfunction in Late-Life Depression	date change Completion moved earlier: 2026-07-30 -> 2026-04-29

New Trial Filings, Last 30 Days

First Posted	Trial	Phase	Status
2026-05-29	NCT07614126 Study of L-dopa Treatment in Patients With a Neurodevelopmental Disorder (CTNNB1 Gene)		Recruiting

Active Studies by Phase

Phase 4

Phase 2

Early Phase 1

Not specified

Active Trials

NCT ID	Title	Condition	Status
Phase 4
NCT06234995	Cortical Electrophysiology of Response Inhibition in Parkinson's Disease	Parkinson Disease	Recruiting
Phase 2
NCT07370532	Etoricoxib in Patients With Parkinsonian Disease	Parkinson Disease	Recruiting
Early Phase 1
NCT05132660	Treating Early Stage Diabetic Retinopathy	Diabetic Retinopathy	Enrolling by Invitation
Not specified
NCT07614126	Study of L-dopa Treatment in Patients With a Neurodevelopmental Disorder (CTNNB1 Gene)	CTNNB1	Recruiting

Sponsors Running Sinemet CR Trials

VA Office of Research and Development (1) Emory University (1) Ihab Elsayed Hassan (1) University Hospital, Montpellier (1)

Disease Areas

Parkinson's Disease (2)

Get alerts when Sinemet CR trials change

Status changes, date slips, and new filings — detected daily, delivered to your inbox.